Get the latest Novavax news, analysis and data today. Stay up-to-date on the latest developments in the fight against COVID-19.
Checkout this video:
Novavax is a pharmaceutical company that specializes in the development of vaccines. The company is headquartered in Gaithersburg, Maryland, and was founded in 1986. Novavax is publicly traded on the Nasdaq stock exchange under the ticker symbol “NVAX.”
Novavax has developed a number of vaccines, including those for influenza, pandemic influenza, and Ebola. The company’s most recent vaccine candidate is for the prevention of respiratory syncytial virus (RSV).
In February 2018, Novavax announced that it had begun Phase III clinical trials for its RSV vaccine candidate in elderly populations in the United States and Australia. If these trials are successful, Novavax could be the first company to bring an RSV vaccine to market.
News about Novavax is often followed closely by investors and the general public alike, as the company’s vaccines have the potential to dramatically improve public health on a global scale.
What is Novavax?
Novavax, Inc. is a clinical-stage vaccine company developing next-generation vaccines to prevent serious viral infections. Novavax is engaged in the development of proprietary recombinant nanoparticle vaccines and adjuvants. The company’s lead adjuvant, Matrix-M, is a licensed technology that improves vaccine response by activating the Toll-like receptor pathway. Novavax’s proprietary virus-like particle (VLP) technology generates ultrapure antigen for incorporation into VLP vaccines.
Novavax News Today
Novavax News Today: What You Need to Know
What Does the Future Hold for Novavax?
The future looks bright for Novavax. The company has a strong pipeline of potential products in development, and its innovative technology platform has the potential to be used for a wide variety of vaccines. Novavax is also continuing to expand its manufacturing capacity, which will be critical to meeting future demand for its products.
In conclusion, Novavax is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infections. The company’s most advanced product is a quadrivalent seasonal flu vaccine, which is currently in Phase III clinical trials. Novavax is also developing other vaccines, including a pandemic flu vaccine and a RSV vaccine.